$CI

ACA Marketplace premiums will rise a median 15% in 2027, following a 20% increase in 2026, totaling a 35% rise in two years. Only one insurer plans to lower premiums. 4.6 million people have canceled plans since June 2025, and 12 insurers, including Cigna, will exit the marketplace in 2027. Rising healthcare costs and loss of subsidies contribute to the increases, affecting affordability for many.

Piper Sandler reiterated an Overweight rating and $370 price target for Cigna (CI), citing undervaluation and analysis of pharmacy fee revenue. Other analysts also raised price targets, highlighting Cigna's 2026 growth outlook and strong segment performance. The stock trades at $310.24 with a P/E ratio of 13.06.

The Cigna Group (CI) reported Q2 2026 revenue of $71.7B (+7% YoY) and adjusted EPS of $7.78 (+8.1% YoY). Management raised 2026 adjusted EPS guidance to at least $30.45. CI trades at a forward P/E of 8.26, lower than CVS Health's 10.67, reflecting market uncertainty about sustained earnings growth. Risks include regulatory pressures and rising healthcare costs.

Cigna Group (CI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 6, 2026, Donna F. Zarcone informed the Board of Directors (the “Board”) of The Cigna Group (the “Company”) that

The Cigna Group (NYSE:CI) will release its Q3 2026 earnings on November 5, 2026, at 6:30 a.m. ET, followed by a conference call at 8:30 a.m. ET. The call will be available via webcast and replay. Financial details will be posted on the company's investor relations website.

Arizona's six remaining ACA marketplace insurers requested rate increases of 25% to 34% for 2027, citing rising medical costs and a sicker risk pool. Cigna is exiting the state's market, affecting 2,500 enrollees. The increases follow the expiration of federal subsidies, leading to higher premiums and reduced enrollment. Final rates are pending regulatory review and will be published by October 31, 2026.

Cigna Healthcare, part of The Cigna Group (CI), launched Health Sense, a support model to reduce inefficient healthcare spending by 10% by 2030. The system connects health, care, and cost data to personalize support. Initial rollout in 2027 will focus on oncology and cardiometabolic health needs, with plans to expand. The company cited existing program results showing higher provider engagement and annual savings of $5,851 for oncology care management.

Piper Sandler kept an Overweight rating on Cigna Group with a $370 price target, suggesting a 38.1% upside from the Oct 1 close. The firm highlights Cigna's long-term EPS growth outlook of 10-14% and a $3B efficiency initiative.

Bernstein raised its price target for Cigna (NYSE:CI) to $387, citing growth in specialty pharmacy. Cigna set 2026-2030 targets, including 10-14% adjusted earnings growth. Q2 2026 earnings beat expectations, with $7.78 EPS and $71.7B revenue. Analysts have mixed outlooks, with UBS targeting $400 and Evercore ISI at $290.

UBS reiterated a Buy rating and $400 price target for Cigna (CI), citing its 2026-2030 outlook. Cigna expects $280B revenue and $30.45 EPS by 2026, with 10-14% EPS growth through 2030. The company also reported Q2 earnings and revenue above estimates. Guggenheim raised its target to $361, while Evercore ISI initiated coverage with a $290 target.